This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Reishi
The "queen mushroom" of Traditional Chinese Medicine — 2,000 years of "calm, longevity, immune" reputation, but human RCT evidence is mostly thin.
Aliases (1)
Overview
What is Reishi?
The "queen mushroom" of Traditional Chinese Medicine — 2,000 years of "calm, longevity, immune" reputation, but human RCT evidence is mostly thin. Best-supported uses: chemo/radiation adjunct (Jin 2016 Cochrane — improved tumor response + QoL, no survival benefit) and clinically diagnosed neurasthenia/fatigue (Tang 2005, 8wk). Sleep and anxiolytic claims are real in rodents (gut-microbiota-serotonin pathway, Yao 2021) but lack human RCT confirmation. For a healthy 20yo MMA athlete: OPTIONAL-ADD / LOW confidence. Mild evening calming effect is real but mild compared to magnesium glycinate, apigenin, or honest sleep hygiene. Three real concerns: (1) anti-platelet activity — drug-interaction risk with NSAIDs/aspirin/warfarin/DOACs, stop 1 week before surgery; (2) ~80% of US retail product is mycelium-on-grain with negligible triterpene content; (3) one case report of severe hepatotoxicity from a powdered product, almost certainly contamination. If using: dual-extract red-reishi fruiting body, 1-3 g/day, brands with third-party β-glucan testing (Real Mushrooms, Nammex-sourced, Host Defense fruiting-body line).
Pharmacokinetics
Peptide Interactions
Most-stacked partner. Cordyceps targets energy/aerobic capacity (CS-4 / militaris improves VO2 indices in small trials), reishi targets calm/immune. No clear…
Lion's mane covers cognitive support (NGF/BDNF signal — also small evidence base), reishi covers evening calm. Different bioactive classes, no interaction.
Both mild calming, both gut-microbiome-friendly. No metabolic conflict. Reasonable evening stack at 200 mg theanine + 1 g reishi.
Classic "stress-cycling" stack — both adaptogens, both evening-leaning. Watch for cumulative sedation if dosed close together. Rotate quarterly rather than s…
Neutral co-administration. Both evening, both calming, no PK interaction. Magnesium glycinate is the bigger lever for most users.
Neutral. Both anti-inflammatory, no PK conflict.
Anti-platelet effects stack — bleeding risk during/after hard training sessions or injury management.
Bleeding risk. Avoid.
Same antiplatelet logic.
Additive antiplatelet effect at high doses. Modest concern at typical 1-2 g/day omega-3 doses.
β-glucan immune priming may interfere with intentional immunosuppression. Avoid without prescriber clearance.
Triterpene metabolism partially through CYP3A4; theoretical exposure increase but no documented clinical interaction.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 7
Side Effects
- 1Mild GI upset — bloating, loose stools, occasional nausea, especially in first 1-2 weeks or at higher doses (2-3 g+). Usually transient; resolves with continued use or dose reduction. Likely related to fiber/β-glucan load on naive gut microbiota.
- 2Dry mouth/throat — common, especially at 1.5+ g/day. Hydrate.
- 3Dizziness or mild lightheadedness — possibly via mild BP-lowering effect.
- 4Mild fatigue / lethargy during the day — usually at >3 g/day; can mean dose is too high.
- 5Skin rash / itching — rare; if present, stop and confirm not allergic to the product or contaminants.
- 6Headache — uncommon, transient.
- 7Insomnia — paradoxical, reported in dopamine.club community data (35 mentions vs 87 sleep-quality positive). Could be from over-stimulation in non-responders, contaminated products, or dosing too close to bedtime in sensitive users.
When to Stop
- Hepatotoxicity case reports — Yuen 2004 (PMID 15464254): single case of severe drug-induced hepatitis attributed to powdered reishi (likely contaminated product or adulteration; rare modern reports with verified dual-extract products from reputable brands). Suggests product purity is the dominant risk vector. Consider baseline ALT/AST if using >3 g/day for >3 months.
- Bleeding events — case reports of post-surgical bleeding and bruising in users on reishi + NSAIDs or reishi + warfarin. The anti-platelet effect of triterpenes is mild but real and additive.
- Allergic reaction / anaphylaxis — rare; people with mushroom allergies should avoid.
- Severe immune-related events — theoretically possible in autoimmune-prone or immunosuppressed users from the β-glucan priming effect, but no convincing case literature.
- Weeks 1-2: GI adjustment — if bloating/loose stools persist beyond 2 weeks, drop dose or stop.
- Weeks 1-4: Skin watch — any rash → discontinue.
- Before any surgery, dental work, or hard sparring session: Stop 7-10 days prior given the platelet effect.
- First 3 months at >2 g/day: Consider baseline + 3-month ALT/AST if you have any other hepatic-risk factor (other supplements, alcohol use, etc.). For Dylan (no alcohol, clean stack): low priority but cheap insurance.
References
Jin X et al. 2016 — Ganoderma lucidum (Reishi mushroom) for cancer treatment, Cochrane systematic review (PMID 27045603)
pooled 5 RCTs (n=373); tumor response 1.5x, QoL benefit, no survival benefit. Best human evidence.
View StudyKlupp NL et al. 2015 — Ganoderma lucidum mushroom for cardiovascular risk factors, Cochrane systematic review (PMID 25686270)
pooled 5 RCTs; no clinically meaningful effect on BP, lipids, glucose, HbA1c in T2D.
View StudyTang W et al. 2005 — Randomized, double-blind, placebo-controlled study of Ganoderma lucidum polysaccharide extract in neurasthenia (PMID 15857210)
8-week, n=132, Ganopoly 5.4 g/day; significant fatigue + well-being improvement.
View StudyYao C et al. 2021 — Ganoderma lucidum promotes sleep through gut-microbiota-dependent serotonergic pathway in mice (PMID 34211003)
rodent mechanism for sleep; microbiota-Bifidobacterium-Tph2 axis.
View StudyQiu Y et al. 2021 — Anti-insomnia mechanism of Ganoderma via central-peripheral multi-level network analysis, BMC Microbiology (PMID 34715778)
34 sedative-hypnotic components, 51 insomnia genes, TNF/CASP3/JUN networks.
View StudyZhang Q, Andoh T et al. 2010 — Inhibitory effect of methanol extract of Ganoderma lucidum on acute itch-associated responses in mice (PMID 20460776)
rodent anti-histamine / mast-cell-stabilizing pharmacology.
View StudyLiu J et al. 2006 — Structure-activity relationship for inhibition of 5-α-reductase by triterpenoids from Ganoderma lucidum (PMID 16962782)
ganoderol B + ganoderic acid DM in-vitro IC50 10-100 µM.
View StudyGao Y et al. 2003 — Effects of Ganopoly on immune functions in advanced-stage cancer patients (PMID 12916709)
open-label 12 weeks; NK cell activity + cytokine modulation.
View StudyWachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. 2011 — Ganoderma lucidum (Lingzhi or Reishi), in Herbal Medicine: Biomolecular and Clinical Aspects (PMID 22593926 / NIH Bookshelf NBK92757)
standard reference compendium; bioactives, mechanism, traditional use.
View StudyYuen MF et al. 2004 — Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi), J Hepatology (PMID 15464254)
case report of severe drug-induced hepatitis; product-quality / contamination concern.
View StudyReal Mushrooms — sourcing guide and Nammex-sourced fruiting-body product line
industry-standard transparency on β-glucan testing and fruiting-body-only sourcing.
View StudyNammex 2017 white paper on the mushroom mycelium-on-grain quality issue
Jeff Chilton's industry critique; β-glucan vs. starch in retail products.
View StudyLatest research
- animalGanoderma lucidum promotes sleep through gut-microbiota-dependent serotonergic pathway in miceGLAA (acidic mycelial extract, 25-100 mg/kg) shortened sleep latency and prolonged sleep in mice; effect eliminated by antibiotic-induced microbiota depletion, mediated via Bifidobacterium enrichment and hypothalamic 5-HT/Tph2 upregulation.
- metaGanoderma lucidum (Reishi mushroom) for cancer treatment (Cochrane systematic review)Jin et al. pooled 5 RCTs (n=373). Reishi as adjunct to chemo/radiotherapy increased tumor-response rate 1.5x and improved QoL (functional/global scales) versus controls. No survival benefit. Recommended only as adjunct, not primary therapy.
- metaGanoderma lucidum mushroom for cardiovascular risk factors (Cochrane systematic review)Klupp et al. pooled 5 RCTs in T2D and metabolic syndrome (n=398). No clinically meaningful benefit for blood pressure, lipids, fasting glucose, or HbA1c. Evidence does not support reishi for CV-risk treatment.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.